MedTrace Logo

Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

NCT03485378 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-09-18

No results posted yet for this study

Summary

This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.

Conditions

Interventions

RADIATION

Stereotactic Ablative Radiotherapy

Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease

Sponsors & Collaborators

  • London Health Sciences Centre

    collaborator OTHER

  • University of British Columbia

    collaborator OTHER

  • Western University, Canada

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • David Palma, MD · London Health Sciences Centre, Lawson Health Research Institute

  • Alexander Louie, MD · London Health Sciences Centre, Lawson Health Research Institute

  • Chris Ryerson, MD · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-20
Primary Completion
2022-01-11
Completion
2026-09-20

Countries

  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03485378 on ClinicalTrials.gov